Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended Southlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS;…
HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes. Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and…
Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming…
Excerpt from the Today Show. Watch the video using the following link: heartsciences.com/wp-content/uploads/2024/02/The-cutting-edge-way-doctors-are-using-AI-to-save-lives_1.mp4
How AI is Reshaping Diagnostic Tools In healthcare, innovation saves lives. From the ECG discovery in 1895 to today's AI breakthroughs, now AI is changing medicine. https://www.techiexpert.com/how-ai-is-reshaping-diagnostic-tools/ SHARE In healthcare,…
Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs…
